Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZYNE Stock Price Chart Interactive Chart >
ZYNE Price/Volume Stats
| Current price | $0.85 | 52-week high | $4.62 |
| Prev. close | $0.82 | 52-week low | $0.82 |
| Day low | $0.85 | Volume | 197,500 |
| Day high | $0.88 | Avg. volume | 487,686 |
| 50-day MA | $1.15 | Dividend yield | N/A |
| 200-day MA | $1.72 | Market Cap | 38.91M |
Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio
Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.
Latest ZYNE News From Around the Web
Below are the latest news stories about ZYNERBA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare ConferenceDEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:00 p.m. ET, and host investor meetings. The conference is being held at the So |
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research SymposiumINSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profileDEVON, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th Interna |
Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment ConferenceDEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022, at 2:00 p.m. ET, and host investor meetings. The conference is |
Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research SymposiumDEVON, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the acceptance of an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium, which will be held in Oslo, Norway, September 8-10, 2022. A copy of the presentation slides will be made available on the Zynerb |
Analysts Offer Insights on Healthcare Companies: Zynerba Pharmaceuticals (ZYNE) and Medios AG (OtherMEDOF)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynerba Pharmaceuticals (ZYNE – Research Report) and Medios AG (MEDOF – Research Report) with bullish sentiments. Zynerba Pharmaceuticals (ZYNE) Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Zynerba Pharmaceuticals today and set a price target of $8.00. The company's shares closed last Wednesday at $1.25, close to its 52-week low of $0.84. According to TipRanks. |
ZYNE Price Returns
| 1-mo | -26.09% |
| 3-mo | -25.44% |
| 6-mo | -58.13% |
| 1-year | -81.03% |
| 3-year | -89.00% |
| 5-year | -89.83% |
| YTD | -70.49% |
| 2021 | -12.73% |
| 2020 | -45.36% |
| 2019 | 103.37% |
| 2018 | -76.28% |
| 2017 | -19.69% |
Continue Researching ZYNE
Here are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...